Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Biomark Neuropsychiatry. 2021 Jun 24;5:100038. doi: 10.1016/j.bionps.2021.100038

Table 4.

Re-analysis of Additional Male Female Difference In Lymphocyte mRNA in Earlier Published Sample (Auta et al, 2013)

mRNA Schizophrenics (CSZ) Controls (NPC) Test
DNMT1
Total Sample 65.80 ± 24.43 (n=27) 49.65 ±16.88 (n=20) TU=2.68, df=44.8, P=0.01
Male 71.93 ± 23.73 (n=21) 54.60 ± 17.78 (n=10) T=2.05 df=29, P=0.05
Female 44.33 ± 11.76 (n=6) 44.70 ±15.20 (n=10) T=.050, df=14, P=0.96
TET1
Total Sample 2.73 ±1.09 (n=25) 1.82± 0.79 (n=18) T=3.00, df=41, P=0.005
Male 2.82 ±1.17 (n=20) 1.76 ± 0.70 (n=7) T=2.25, df=25, P=0.034
Female 2.35 ± 0.69 (n=5) 1.86± 0.87 (n=11) T=1.110, df=14, P=0.29
BDNF
Total Sample 0.26 ± 0.15 (n=18) 0.38 ± 0.16 (n=11) T=2.01, df=27, P=0.055
Male 0.22 ± 0.10 (n=11) 0.44 ± 0.18 (n=5) T=3.32, df=14, P=0.005
Female 0.34 ± 0.19 (n=7) 0.33 ± 0.13 (n=6) T=0.11, df=11, P=0.91

Each value represents Mean ± S.D. T= independent sample T-test. TU= independent sample T-test for unequal variances.